Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up

By PR Newswire12 days ago

OSLO, Norway, Feb. 23, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces 21-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with...

Continue read on prnewswire.com